×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:AMPH

Amphastar Pharmaceuticals Stock Forecast, Price & News

$31.78
-0.96 (-2.93%)
(As of 06/24/2022 04:00 PM ET)
Add
Compare
Today's Range
$31.52
$33.00
50-Day Range
$29.79
$41.54
52-Week Range
$17.56
$44.46
Volume
1.26 million shs
Average Volume
510,695 shs
Market Capitalization
$1.55 billion
P/E Ratio
19.74
Dividend Yield
N/A
Price Target
$36.67
30 days | 90 days | 365 days | Advanced Chart

Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Stock Forecast (MarketRank)

Overall MarketRank

2.41 out of 5 stars

Medical Sector

187th out of 1,418 stocks

Pharmaceutical Preparations Industry

75th out of 679 stocks

Analyst Opinion: 2.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
Amphastar Pharmaceuticals logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,761
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
6/24/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$36.67
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+15.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
3 Analysts

Profitability

Net Income
$62.12 million
Pretax Margin
23.74%

Debt

Sales & Book Value

Annual Sales
$437.77 million
Cash Flow
$1.92 per share
Book Value
$9.31 per share

Miscellaneous

Free Float
35,255,000
Market Cap
$1.55 billion
Optionable
Optionable
Beta
0.65














Amphastar Pharmaceuticals Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2022?

3 brokers have issued 1-year price objectives for Amphastar Pharmaceuticals' stock. Their AMPH stock forecasts range from $32.00 to $43.00. On average, they predict Amphastar Pharmaceuticals' stock price to reach $36.67 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Amphastar Pharmaceuticals' stock price performed in 2022?

Amphastar Pharmaceuticals' stock was trading at $23.29 at the beginning of the year. Since then, AMPH shares have increased by 36.5% and is now trading at $31.78.
View the best growth stocks for 2022 here
.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Amphastar Pharmaceuticals
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings data on Monday, May, 9th. The company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.14. The business earned $120.37 million during the quarter, compared to the consensus estimate of $110.60 million. Amphastar Pharmaceuticals had a net margin of 17.87% and a trailing twelve-month return on equity of 17.35%. During the same period in the prior year, the company earned $0.27 EPS.
View Amphastar Pharmaceuticals' earnings history
.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:
  • Dr. Ziping Luo Ph.D., Chairman, Chief Scientist & COO (Age 72, Pay $1.34M)
  • Dr. Yongfeng Zhang Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 75, Pay $1.93M)
  • Mr. William J. Peters M.B.A., CFO, Exec. VP of Fin. & Treasurer (Age 54, Pay $1.11M) (LinkedIn Profile)
  • Mr. Jacob Liawatidewi M.B.A., Exec. VP of Sales, Marketing & Corp. Admin. Center and Corp. Sec. (Age 48, Pay $773.69k)
  • Mr. Rong Zhou M.S., Exec. VP of Production Center (Age 63, Pay $842.77k) (LinkedIn Profile)
  • Dan Dischner, VP of Corp. Communications
  • Tony Marrs, Sr. VP of Regulatory Affairs and Clinical Operations
  • Mr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 69)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.55%), Federated Hermes Inc. (7.14%), Vanguard Group Inc. (5.09%), Dimensional Fund Advisors LP (3.68%), State Street Corp (2.71%) and Nantahala Capital Management LLC (0.00%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals
.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Assenagon Asset Management S.A., Eagle Asset Management Inc., BlackRock Inc., SG Americas Securities LLC, Arrowstreet Capital Limited Partnership, and Nisa Investment Advisors LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last two years include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Hillsdale Investment Management Inc., Penserra Capital Management LLC, Friess Associates LLC, EAM Investors LLC, Calamos Advisors LLC, and Acadian Asset Management LLC.
View insider buying and selling activity for Amphastar Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $31.78.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $1.55 billion and generates $437.77 million in revenue each year. The company earns $62.12 million in net income (profit) each year or $1.61 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,761 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for Amphastar Pharmaceuticals is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.